• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Alcami

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Cytovance Biologics

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Real World Evidence Developments Across the Globe

    This article investigates how Real World Data and Real World Evidence are evolving across the U.S., Europe and Asia.

    Real World Evidence Developments Across the Globe
    Related CONTENT
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • Mogene
    • Softweb Solutions
    • Reed-Lane
    • KASA to Support Generic Drug Review
    Madhur Garg, Real World Evidence and Market Access, Sciformix, a Covance Company04.05.19
    The emergence of value based payments (VBP) has highlighted the importance and relevance of real world evidence (RWE). RWE is used to assess a product’s safety, efficacy to effectiveness translation, cost effectiveness and product differentiation,1,2 thus helping payers and manufacturers to implement ‘performance-based risk-sharing agreements’ and patients to manage budgets and estimate risk benefit of interventions. Manufacturers can leverage RWE to obtain accelerated market access and it can facilitate payers in substantiating drug pricing and reimbursement. Real World Data (RWD) can help with regulatory approval of label expansion or new indications for marketed drugs.

    However, the approach to collecting, evaluating and using RWD around the globe is very inconsistent. There is an increasing desire among a wide range of stakeholders—including industry, regulators, payers, providers and patients—to harmonize its use and impact for the overall benefit of patients. This article investigates how RWD and RWE are evolving across the U.S., Europe and Asia.

    The U.S. Perspective
    The FDA has stated the need to ‘close the evidence gap between the information it uses to make decisions and the evidence increasingly used by payers and others charged with making healthcare decisions.’ As the government is the largest payer in the U.S., the need for regulators and payers to align more closely is particularly acute.

    The 21st Century Cures Act (Section 3037) amended the U.S. FDA Modernization Act 114, allowing manufacturers to use RWE to support a new indication for an approved drug. By utilizing comparative Patient Reported Outcomes (PRO) data and Health Care Economic Information (HCEI), manufacturers can communicate a wider scope of a product’s value to payers and formulary decision-makers. This change lowered the threshold required for proactive communication from ‘substantial evidence’ to ‘competent and reliable scientific evidence’.

    In September 2016, draft Guidance was published by the FDA on the use of RWE to support regulatory decision making for medical devices.3 The guidance states the FDA will evaluate the regulatory relevance of the RWD, as well as the reliability and quality of the data and data sources. Medical device manufacturer, Medtronic, signed performance to payment contracts requiring the company to reimburse hospitals for selected costs if Tyrx’s antibacterial envelope fails to prevent infection in patients who receive cardiac implants. In the recently launched working model of Pre-Cert Program for software as a medical device (SaMD), the FDA emphasized that the collection of real world performance data (RWPD) will enable pre-certified manufacturers either an exemption from pre-market review for lower risk products, or a faster review of the higher risk ones.4

    The FDA aims to publish draft guidance for the use of RWE by October 2021.5 In 2018, the Institute for Clinical and Economic Review (ICER), in collaboration with the Office of Health Economics (OHE), produced guidance to payers and manufacturers on the development and use of RWE for drug coverage and formulary decisions.6 It suggests the formulation of a prospective protocol, entailing contextual considerations to define the evidentiary assertion and associated evidence bar for RWE. Other examples of how RWE is being used by industry, regulators, payers and providers in the U.S. is detailed in Table 1.


    Table 1. Examples of RWE in use by industry, regulators, payers and providers in the US

    RWE in Europe is generally used for accelerated access to medicines and reassessment or review post launch. In the UK, the Medicines & Healthcare products Regulatory Agency (MHRA) accepts RWE as supplementary to phase 2 and phase 3 data, as well as in cases of ongoing evidence collection. However, in Germany, the Federal Institute for Drugs and Medical Devices (BfArM) maintains that Randomized Control Trial (RCT) data is the only drug-specific evidence available prior to market authorization. Other European countries have various challenges, including: limited access to data and sub-optimal IT infrastructure; long and complex reimbursement processes; and registries that are not well connected or managed. There are several pan-European initiatives underway to drive adoption of RWE as detailed in Table 2.


    Table 2. European initiatives underway to drive adaoption of RWE


    The Asia Perspective
    According to IMS Health, data supply issues including availability, completeness and quality, as well as gaining trust of data owners are the main challenges in Asia.11 However, some data is already available and being used, or planned, as shown in Table 3.


    Table 3. Data already available and being used, or planned, across Asia

    Across Asia, much like Europe, acceptance, use and knowledge of RWE is very mixed. Countries such as Japan, Singapore and Australia with advanced medical and health related infrastructure are also comparably quite advanced in the development and adoption of RWE, whereas countries like India and China are less so.15

    In 2017, Japan began its “Rational Medicine” initiative which aims to make the Japanese health care system more patient-centric and evidence-based. According to the chief executive of Japan’s Pharmaceuticals and Medical Devices Agency, it has the goals of providing “better insight into the risk/benefit balance of drugs, medical devices, and regenerative medical products” and creating “a medical environment where the care provided is strictly evidence based.”

    Singapore’s Health Sciences Authority (HSA) launched an adaptive licensing initiative called New Drug Development Paradigms (NEWDIGS) in 2013 in collaboration with the Massachusetts Institute of Technology (MIT). Due to its small size and modern infrastructure, it is a global leader in adverse event monitoring through its hospital databases, so is well placed for further adoption of RWE.

    In 2012, Australia launched its e-health program, in which it invested more than AU$1 billion and launched Australia’s Personally Controlled Electronic Health Records (PCEHR), now called My Health Record.16 Its aim was to make the health system more agile and sustainable and allow healthcare organizations to have faster, easier access to more health information for improved treatment decisions. However, widespread adoption and use of the system is still a way off, with concerns about usability and patients’ online literacy thought to be impacting uptake.17

    In China, while there are registries for infectious diseases and rich hospital-level data, hospital information systems are not standardized and data is not consistently captured. In some cases medical records and files are not fully digitized, making the data even harder to access. However, with the use of modern technology such as wearable devices on the rise, the potential value of RWD is likely to influence future healthcare reform.

    In India, data sources are limited. For example, health claims data is scant due to low adoption of health insurance and EHRs along with 60% of the population living rurally. As healthcare in India is not financed by the Government, databases, medical records, and other sources of RWD have remained undeveloped. However, the Indian Health Ministry is developing legislation that would help India move toward the development and use of EHRs and improve the country’s ability to collect and store personal health data.

    Summary
    It is clear a multi-stakeholder approach with international collaboration is essential to ensuring robust RWE generation and utilization. Global pharmaceutical companies play a pivotal role in encouraging standardization of concepts, processes and approaches for RWE. A key imperative for organizations is to strategically utilize digital technology and artificial intelligence to enhance data availability for RWE generation. There are some additional examples of how blockchain and data analytics, within RWE, will be used to incentivize right health outcomes in the healthcare ecosystem.18,19

    Recent developments in the mergers and acquisitions (M&A) space have showed enough investor appetite towards funding game-changing health delivery models. An example of this includes Amazon’s acquisition of online pharmacy PillPack which looks at removing the middlemen in the pharmacy supply chain. The Amazon, JPMorgan Chase and Berkshire Hathaway joint venture has indicated its aim to lower health insurance coverage costs for employees among other things.20 These examples show, overall, RWE will be a key driver in the transition towards value based healthcare.

    It may not be possible for companies to invest in all areas of expertise required to take advantage of growth in RWE. Hence, identifying areas that are core will help determine the right partners they need to look for. Analytics and modeling, tools to aid analytics, capture of real world data, systematic review and synthesis of information, building parts of the core value dossier are a few examples of activities that can be outsourced effectively. It is also important for the partners to understand the client’s portfolio and the value development framework for the products so that they can deliver the services in the most meaningful and effective manner. 

    References
    1. Alison Cave, 2016. What are the real-world evidence tools and how can they support decision making.
    2. U.S. Department of Health and Human Services, Food and Drug Administration, 2017. Use of Real-World Evidence to support regulatory decision-making for medical devices.
    3. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices –Draft Guidance, FDA, September, 2016
    4.https://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM597303.pdf
    5.https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM511438.pdf
    6. ICER (2018). Real World Evidence for Coverage Decisions: opportunities and challenges / Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real World Evidence for Coverage and Formulary Decisions
    7. http://www.imi-getreal.eu/News/ID/88/European-Commission--a-succes-story-IMI-GetReal
    8. https://www.eunethta.eu/ja3-archive/work-package-5-life-cycle-approach-to-improve-evidence-generation/ 
    9.http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp
    10. Gill, J.L., d’Angela, D., Berger, K., Dank, M., Duncombe, R.,Fink-Wagner, A-H., Hutton, J., Kössler, I., Podrazilova, K.,Thomas, M. and Kanavos, P.G. (2017). RWE in Europe Paper IV: engaging pharma in the RWE Roadmap.
    11. Tan, Seng C. (2015) Staying ahead of your competitors in evidence-based world: models for success.
    12. http://www.ncdirindia.org/ncrp/About_NCRP.aspx
    13. http://www.phrn.org.au/
    14. Lateral Economics (October 2017). Population Health Research Network (PHRN) Impact and Return on Investment.
    15. https://www.pharmafocusasia.com/clinical-trials/use-real-world-evidence
    16. https://www.myhealthrecord.gov.au/
    17. Walsh, Louisa et al. “The E-Health Literacy Demands of Australia’s My Health Record: A Heuristic Evaluation of Usability.” Perspectives in Health Information Management 14.Fall (2017): 1f. Print.
    18. Healthcare transaction validation via blockchain proof-of-work, systems and methods, 2015. (Internet) https://patentimages.storage.googleapis.com/72/da/6f/95585e5e8709c3/US20150332283A1.pdf 
    19. Healthcare IT News, 2018. Why Walmart filed a patent for blockchain, wearables and EHR data (Internet) https://www.healthcareitnews.com/news/why-walmart-filed-patent-blockchain-wearables-and-ehr-data
    20. Amazon’s Acquisition of PillPack, 2018 (Internet) http://www.globallegalchronicle.com/amazons-acquisition-of-pillpack/



    Madhur Garg is the Director of Real World Evidence and Market Access at Sciformix, a Covance Company
    Related Searches
    • Pharma
    • outsourced
    • artificial intelligence
    • quality
    Suggested For You
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Reed-Lane Reed-Lane
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    Myoderm Announces Leadership Transition Myoderm Announces Leadership Transition
    Synthetic Control Arms Synthetic Control Arms
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?
    BASi Announces New CCO BASi Announces New CCO
    Sygnature Discovery Makes Key Appointments Sygnature Discovery Makes Key Appointments
    BASi Appoints COO BASi Appoints COO
    Akorn Receives FDA Warning Letter Akorn Receives FDA Warning Letter
    SHYFT Analytics, PAREXEL Enter Strategic RWE Pact SHYFT Analytics, PAREXEL Enter Strategic RWE Pact
    Janssen Receives FDA Approval for INVOKANA Janssen Receives FDA Approval for INVOKANA
    Alcami Collaborates with Medicines Development for Global Health Alcami Collaborates with Medicines Development for Global Health

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Pfizer, BioNTech Enter Vax Pact With COVAX
    • CONTINUUS Awarded $69.3M DoD Grant
    • Piramal Inks Clinical Supply Deal With Theratechnologies
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login